Skip to main content

The I-SPARC study

News :13/06/2022

Do you want to contribute to research to combat the Coronavirus (COVID-19) among cancer patients?

The I-SPARC study
The I-SPARC clinical trial aims to evaluate the immune response among cancer patients after administering at least two doses and possibly a booster dose of an RNA messenger vaccine against COVID-19 (Pfizer/BioNTech vaccine or Moderna vaccine).*   

This international clinical trial is being conducted by the Jules Bordet Institute. 500 men and women volunteers aged 18 and over will participate. 

Why participate in this clinical trial?
To date, few clinical trials have studied protection against the virus following anti-SARS-CoV-2 vaccination among cancer patients and the Jules Bordet Institute would like to obtain more information on this subject. 

By participating in this study, the level of antibodies and possibly lymphocytes present in the blood to combat SARS-CoV-2 will be monitored.

(*) The booster dose will be administered in accordance with your course of vaccinations as recommended by the national guidelines. 

  • If you are interested in participating in this study or if you would like further information, we invite you to discuss it with your doctor at the Jules Bordet Institute or to contact: 
    • V. Coubeaux (coordinating nurse) 02/541.37.08
    • Dr A. Loizidou (coordinating doctor) 02/541.72.11 between 2 pm and 3.30 pm